TP protocol clinical trials
How each study uses TP protocol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TP protocol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TP regimen
- 2
Studies by the year they started
5 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Fudan University (1) · Xiuping Ding (1) · University of Erlangen-Nürnberg Medical School (1) · Sichuan Provincial People's Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1)
Often tested with
Tested in the same studies.
Adebrelimab (1) · Docetaxel/Doxorubicin Regimen (1) · Doxorubicin/Paclitaxel Regimen (1) · Nimotuzumab (1)
Studies
Open first, then newest update. How each study uses TP protocol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Xiuping DingNCT07055841Written as TP regimenHow we know
- Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck CancerTerminatedPhase 3University of Erlangen-Nürnberg Medical SchoolNCT01126216Written as Paclitaxel/CisplatinHow we know
- AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast CancerStatus unknownPhase 2Sichuan Provincial People's HospitalNCT04499118Written as TP regimenHow we know
- Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)CompletedPhase 3Fudan UniversityNCT01216111Written as Paclitaxel CisplatinHow we know
- Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC PatientsStatus unknownNot applicableTianjin Medical University Cancer Institute and HospitalNCT01393080Written as Nimotuzumab and TP regimenHow we know
Given beside what is tested · 4 — TP protocol is usual care or a partner of the new treatment
- CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCRecruitingPhase 3Fudan UniversityNCT06964568Written as TP regimenHow we know
- A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.Not yet recruitingNot applicableShandong Cancer Hospital and InstituteNCT06649448Written as TP regimenHow we know
- Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerCompletedPhase 2Mian XINCT04005170Written as Paclitaxel/CisplatinHow we know
- Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerStatus unknownPhase 2Jianhua FuNCT04006041Written as Paclitaxel/cisplatinHow we know
As the comparator · 3 — what is tested is compared with TP protocol
- An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07709533Written as Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitorHow we know
- Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)CompletedPhase 3Haruhiko FukudaNCT00295789Written as chemotherapy: Paclitaxel/CisplatinHow we know
- Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical CarcinomaStatus unknownPhase 3Institut fuer FrauengesundheitNCT01405235Written as Cisplatin/PaclitaxelHow we know